Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Vertex Pharmaceuticals” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 159
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 159 pipeline programs matching "Vertex Pharmaceuticals" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

159 results for “Vertex Pharmaceuticals” Back to intelligence hub

Search results

Page 4 of 7
  1. VX-121

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial
  2. VX-135

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    3 trials
  3. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Glomerulosclerosis, Focal Segmental

    phase 2 small molecule completed

    1 trial
  4. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Osteoarthritis

    phase 2 small molecule completed

    1 trial
  5. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    2 trials
  6. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Small Fiber Neuropathy

    phase 2 small molecule completed

    1 trial
  7. VX-152

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial
  8. VX-222

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C Virus

    phase 2 small molecule completed

    2 trials
  9. VX-264

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial
  10. VX-264 Implant

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial
  11. VX-371

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Ciliary Dyskinesia

    phase 2 small molecule completed

    1 trial
  12. VX-371 + HS

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial
  13. VX-407

    Vertex Pharmaceuticals (Australia) Pty.

    Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    phase 2 small molecule active

    4 trials
  14. VX-407 tablet

    Vertex Pharmaceuticals (Australia) Pty.

    Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    phase 2 small molecule active

    1 trial
  15. VX-522 mRNA therapy

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial
  16. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Painful Lumbosacral Radiculopathy

    phase 2 small molecule completed

    1 trial
  17. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    2 trials
  18. VX-561

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule terminated

    2 trials
  19. VX-659

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials
  20. VX-661

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials
  21. VX-670

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy Type 1 (DM1)

    phase 2 small molecule active

    2 trials
  22. VX-670 Solution for Injection/Infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial
  23. VX-702

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials
  24. VX-765

    Vertex Pharmaceuticals (Australia) Pty.

    Psoriasis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.